HC Wainwright Reaffirms Buy Rating for Poseida Therapeutics (NASDAQ:PSTX)

Poseida Therapeutics (NASDAQ:PSTX)‘s stock had its “buy” rating restated by HC Wainwright in a report issued on Wednesday, Benzinga reports. They currently have a $20.00 price target on the stock. HC Wainwright also issued estimates for Poseida Therapeutics’ Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.51) EPS and FY2028 earnings at $0.26 EPS.

Poseida Therapeutics Trading Down 3.6 %

PSTX opened at $2.95 on Wednesday. The firm has a 50 day simple moving average of $2.78 and a 200 day simple moving average of $3.02. The company has a debt-to-equity ratio of 0.69, a current ratio of 2.56 and a quick ratio of 2.56. The company has a market cap of $286.03 million, a price-to-earnings ratio of -2.48 and a beta of 0.46. Poseida Therapeutics has a fifty-two week low of $1.54 and a fifty-two week high of $4.27.

Poseida Therapeutics (NASDAQ:PSTX) last released its quarterly earnings results on Thursday, March 7th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.09. The firm had revenue of $25.00 million for the quarter, compared to the consensus estimate of $12.50 million. Poseida Therapeutics had a negative return on equity of 97.36% and a negative net margin of 131.95%. On average, sell-side analysts anticipate that Poseida Therapeutics will post -1.66 earnings per share for the current year.

Hedge Funds Weigh In On Poseida Therapeutics

A number of hedge funds have recently modified their holdings of the business. Silverarc Capital Management LLC increased its position in shares of Poseida Therapeutics by 21.1% during the third quarter. Silverarc Capital Management LLC now owns 3,567,985 shares of the company’s stock worth $8,492,000 after buying an additional 622,037 shares during the period. Vanguard Group Inc. increased its stake in Poseida Therapeutics by 16.3% during the 1st quarter. Vanguard Group Inc. now owns 3,373,065 shares of the company’s stock valued at $10,760,000 after purchasing an additional 473,746 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its position in Poseida Therapeutics by 89.4% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 830,127 shares of the company’s stock valued at $2,648,000 after acquiring an additional 391,801 shares in the last quarter. Blair William & Co. IL boosted its position in shares of Poseida Therapeutics by 41.3% during the first quarter. Blair William & Co. IL now owns 965,052 shares of the company’s stock valued at $3,079,000 after buying an additional 282,310 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Poseida Therapeutics by 186.7% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 342,857 shares of the company’s stock valued at $816,000 after purchasing an additional 223,280 shares during the last quarter. Institutional investors and hedge funds own 46.87% of the company’s stock.

About Poseida Therapeutics

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.